Cholangiocarcinoma: Clinical Trials

55 trials for Cholangiocarcinoma, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

15 unknown, 10 terminated, 8 active not recruiting, 8 recruiting. 55 Phase 3, 17 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 355Unknown 15, Terminated 10, Active not recruiting 8, Recruiting 8, Completed 7, Not yet recruiting 6, Withdrawn 1
Phase 217Unknown 5, Active not recruiting 4, Recruiting 4, Not yet recruiting 2, Terminated 2

Follow Cholangiocarcinoma: new trials by email Literature Review of Cholangiocarcinoma trials Research Report on Cholangiocarcinoma

Trials (filtered) newest first · largest first

All 55 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Testing the Addition of Ivonescimab Combined With Standard Chemotherapy Compared to the Usual Chemotherapy and Immunotherapy Treatment for Patients With Advanced Biliary Tract Cancer
Biospecimen Collection, Cisplatin, Computed Tomography - Locally Advanced Biliary Tract Adenocarcinoma, Locally Advanced Extrahepatic Cholangiocarcinoma
Phase 2 / Phase 3Not yet recruitingECOG-ACRIN Cancer Research Group3362027-01-112026-08-14
Investigating Precision Medicine in the Adjuvant Setting in Biliary Tract Cancer
Futibatinib, Ivosidenib + Capecitabine, Zanidatamab + Capecitabine - Biliary Tract Cancer (BTC)
Phase 3Not yet recruitingUNICANCER9902027-01-022026-08-04
Hepatic Arterial Infusion Chemotherapy Versus Capecitabine as Adjuvant Therapy for Resected Biliary Tract Cancer
Oxaliplatin, 5-Fluorouracil, Capecitabine - Biliary Tract Cancer, Cholangiocarcinoma
Phase 3Not yet recruitingZhai Wenlong902026-11-302026-11-04
Intraarterial Therapies Plus Tislelizumab Plus Lenvatinib Versus Tislelizumab Plus Gemcitabine-Cisplatin in Unresectable Intrahepatic Cholangiocarcinoma
Gemcitabine, Cisplatin, Tislelizumab - Intrahepatic Cholangiocarcinoma (Icc)
Phase 3Not yet recruitingZhejiang Cancer Hospital1402026-09-012026-10-26
D07001 Softgel-Capsules and Capecitabine Combination Therapy in Patients With Advanced Biliary Tract Cancer
D07001-Softgel Capsules, Placebo, Capecitabine - Biliary Tract Cancer (BTC)
Phase 3RecruitingInnoPharmax Inc.2402026-06-092026-11-04
Study of Becotatug Vedotin Added to Standard Treatment for Advanced Bile Duct Cancer With EGFR Mutations
Becotatug Vedotin, Pucotenlimab, Gemcitabine - Cholangiocarcinoma
Phase 2 / Phase 3Not yet recruitingSir Run Run Shaw Hospital1642026-05-202026-05-20
A Study to Select a Dose Regimen (Part A) and to Investigate Overall Survival (Part B) With Nanvuranlat Compared With Physician's Best Choice in Participants Aged 18 Years or Older With Biliary Tract Cancer
Nanvuranlat, Physician's Best Choice - Advanced Biliary Tract Cancer, Biliary Tract Cancer (BTC)
Phase 3RecruitingJ-Pharma Co., Ltd.4802026-05-112026-09-29
Neoadjuvant Gemcitabine and Cisplatin in Combination With Perioperative Pembrolizumab Versus Upfront Surgery for Patients With Primary Resectable and Borderline Resectable Perihilar and Distal Cholangiocarcinoma
Pembrolizumab, Gemcitabine, Cisplatin - Extrahepatic Cholangiocarcinoma, Perihilar Cholangiocarcinoma
Phase 2 / Phase 3RecruitingAmsterdam UMC, location VUmc1502026-04-172026-08-25
Efficacy and Safety of TT-00420 (Tinengotinib) Tablets Versus Chemotherapy in Patients With Advanced Intrahepatic Cholangiocarcinoma Harboring FGFR2 Fusions/Rearrangements or Mutations
TT-00420 (tinengotinib), Oxaliplatin, fluorouracil, calcium folinate, irinotecan, capecitabine - Intrahepatic Cholangiocarcinoma (Icc), Advanced Cholangiocarcinoma
Phase 3Not yet recruitingTransThera Sciences (Nanjing), Inc.1382026-01-012026-01-09
Trop2-targeted immunoPET Imaging of Solid Tumors
[68Ga]Ga-NOTA-T4, [68Ga]Ga-NOTA-RT4, [18F]F-RESCA-T4 - Solid Tumor, Solid Carcinoma
Phase 2 / Phase 3RecruitingRenJi Hospital4002024-12-232026-05-29
The Effect of [18F] F-FAPI PET-CT on Management in Patients With Proximal Cholangiocarcinoma
[18F]F-FAPI PET-CT - Cholangiocarcinoma
Phase 2 / Phase 3RecruitingMara Veenstra, MD812024-11-292025-04-11
Futibatinib in Patients Previously Enrolled in an Antecedent Futibatinib as Monotherapy or Combination Therapy.
futibatinib, futibatinib, fulvestrant - Advanced/Metastatic Cancer
Phase 2 / Phase 3Active not recruitingTaiho Oncology, Inc.152024-10-012026-07-28
Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer
Zanidatamab, Cisplatin, Gemcitabine - Biliary Tract Cancer
Phase 3RecruitingJazz Pharmaceuticals2862024-07-192026-11-19
Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma
Tinengotinib 8 mg, Tinengotinib 10 mg, Physician's Choice - Cholangiocarcinoma
Phase 3Active not recruitingTransThera Sciences (Nanjing), Inc.2002023-12-202026-07-06
Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)
Rilvegostomig, Placebo, Capecitabine - Biliary Tract Cancer
Phase 3Active not recruitingAstraZeneca7602023-12-042026-10-16
CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative Chemotherapy Versus Immediate Resection in patIents With resecTable BiliarY Tract Cancers (BTC) at High Risk for Recurrence
Gemcitabine, Nab paclitaxel, Cisplatin - Biliary Tract Cancer, Cholangiocarcinoma
Phase 2 / Phase 3RecruitingGruppo Oncologico del Nord-Ovest3002023-11-072026-09-09
Toripalimab Plus Lenvatinib and Gemcitabine-based Chemotherapy in 1L Treatment of Advanced ICC: a Phase III Study
Toripalimab, Lenvatinib mesylate capsules, Placebo IV - Intrahepatic Cholangiocarcinoma
Phase 3RecruitingShanghai Junshi Bioscience Co., Ltd.4802023-06-192025-04-23
An Early Access Study of Ivosidenib in Patients With a Pretreated Locally Advanced or Metastatic Cholangiocarcinoma
Ivosidenib Oral Tablet - Cholangiocarcinoma
Phase 3Active not recruitingServier Affaires Médicales2992023-05-032026-07-31
A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002)
CTX-009, Paclitaxel - Biliary Tract Cancer, Cholangiocarcinoma
Phase 2 / Phase 3Active not recruitingCompass Therapeutics1682023-01-092026-11-10
Study of SMT-NK Inj. Plus Pembrolizumab vs Pembrolizumab Monotherapy in Patients With Advanced Biliary Tract Cancer
SMT-NK inj.+Pembrolizumab, Pembrolizumab - Biliary Tract Cancer
Phase 2 / Phase 3UnknownSMT bio Co., Ltd.1282022-06-092022-09-27

Showing 20 of 55. Sign in to see all of them.

Narrower conditions

Gallbladder Neoplasms (14)  ·  Biliary Tract Neoplasms (13)  ·  Bile Duct Neoplasms (7)  ·  Klatskin Tumor (4)  ·  Neoplasms (4)  ·  Adenocarcinoma (2)  ·  Carcinoma, Hepatocellular (2)  ·  Cirrhosis, Familial, with Pulmonary Hypertension (2)  ·  Liver Neoplasms (2)  ·  Neoplasm Metastasis (2)  ·  Parkinson Disease 4, Autosomal Dominant Lewy Body (2)  ·  Urinary Bladder Neoplasms (2)  ·  Uterine Cervical Neoplasms (2)  ·  Anus Neoplasms (1)

Broader conditions

Neoplasms by Histologic Type (55)  ·  Neoplasms, Glandular and Epithelial (55)  ·  Carcinoma (54)  ·  Adenocarcinoma (53)  ·  Neoplasms (51)  ·  Digestive System Diseases (25)  ·  Neoplasms by Site (25)  ·  Digestive System Neoplasms (24)  ·  Biliary Tract Diseases (22)  ·  Gallbladder Diseases (14)  ·  Biliary Tract Neoplasms (9)  ·  Bile Duct Diseases (7)  ·  Pathological Conditions, Signs and Symptoms (5)  ·  Pathologic Processes (4)  ·  Liver Diseases (3)

Interventions

Gemcitabine (25)  ·  Cisplatin (20)  ·  Capecitabine (10)  ·  Oxaliplatin (9)  ·  pembrolizumab (7)  ·  Fluorouracil (6)  ·  Leucovorin (6)  ·  Photochemotherapy (5)  ·  Irinotecan (3)  ·  ivosidenib (3)  ·  1,2-diaminocyclohexaneplatinum II citrate (2)  ·  Albumin-Bound Paclitaxel (2)  ·  Cholangiopancreatography, Endoscopic Retrograde (2)  ·  Drug Therapy (2)  ·  Neoadjuvant Therapy (2)

Sponsors

Merck Sharp & Dohme LLC (2)  ·  Shanghai Zhongshan Hospital (2)  ·  Shi Ming (2)  ·  TransThera Sciences (Nanjing), Inc. (2)  ·  Weill Medical College of Cornell University (2)  ·  Air Force Military Medical University, China (1)  ·  Amsterdam UMC, location VUmc (1)  ·  Asan Medical Center (1)  ·  AstraZeneca (1)  ·  Changhai Hospital (1)  ·  Compass Therapeutics (1)  ·  Concordia Laboratories Inc. (1)  ·  Dan Zandberg (1)  ·  Delcath Systems Inc. (1)  ·  ECOG-ACRIN Cancer Research Group (1)

Countries

China (23)  ·  United States (23)  ·  United Kingdom (15)  ·  France (14)  ·  Italy (14)  ·  South Korea (14)  ·  Spain (13)  ·  Germany (12)  ·  Canada (10)  ·  Belgium (9)  ·  Australia (8)  ·  Netherlands (8)  ·  Taiwan (8)  ·  Japan (6)  ·  Austria (4)

Top investigators

Michel Kahaleh, MD (3)  ·  Afshin Dowlati, MD (1)  ·  Changping Wu, M.D. (1)  ·  Criss Cheng (1)  ·  Cynthia Sirard, MD (1)  ·  Dan Zandberg, MD (1)  ·  Deirdre J Cohen (1)  ·  Do Hyun Park, MD, PhD (1)  ·  Eric K Rowinsky, MD (1)  ·  Gaojun Teng, MD (1)  ·  Ghassan Abou-Alfa, MD (1)  ·  Guohong Han, MD,Ph.D (1)  ·  Harpreet Wasan, MD (1)

Results publications

PMID 40812353, PMID 42176183, PMID 15691639, PMID 20165987, PMID 20375404, PMID 23703448, PMID 24485665, PMID 25456367, PMID 26228433, PMID 26503201, PMID 30785198, PMID 30914290, PMID 30998813, PMID 32374623, PMID 32461347, PMID 32580579, PMID 32677452, PMID 33798493, PMID 34515993, PMID 34554208, PMID 35935821, PMID 37075781, PMID 37368098, PMID 38278871, PMID 38589856, PMID 38661512, PMID 38689424, PMID 38861293, PMID 38875119, PMID 39206260, PMID 39671534, PMID 39978598, PMID 40154623, PMID 40268484, PMID 41469668, PMID 41646284, PMID 41780001, PMID 42223137, PMID 8708722

NIH funding

2019 (3), 2023 (3), 2018 (2), 2025 (1), U10CA180820 (1), U10CA180868 (1), U10CA180888 (1)